TrialThe New England journal of medicine2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Rachelle S Doody et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
841 papers cite itlatest 60 shown
this paperpooled ittrialcites it